Canakinumab might be Protective against Severe COVID-19 for Patients with Autoinflammatory Disorders

Alkan, Arif; Uğurlu, Serdal

doi:10.31138/mjr.33.2.237

Cited by 1 publication

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, except for the CANTOS trial, the rest available data are rather limited and, most importantly, conflicting. In addition, in the era of coronavirus disease-2019 and its strong relationship with hyper-inflammation, it still has to be determined whether these agents can prevent short- and long-term cardiovascular complications of the disease, based on their widespread use in the acute setting of severe disease [ 83 , 84 , 85 ].…”

Section: Future Perspectives and Concluding Remarksmentioning

confidence: 99%

Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence

Dimosiari

Patoulias

Kitas

et al. 2023

JCM

View full text Add to dashboard Cite

Cardiovascular disease (CVD) constitutes a real pandemic of the 21st century. According to data from the Centers for Disease Control and Prevention, one person dies every 34 min due to some form of CVD in the United States. Apart from the extremely high morbidity and mortality accompanying CVD, the economic burden seems to be unbearable even for developed countries in the Western World. The role of inflammation in the development and progression of CVD appears to be crucial, while, various inflammatory pathways, such as the Nod-like receptor protein 3 (NLRP3) inflammasome-interleukin (IL)-1/IL-6 pathway of the innate immunity, have attracted scientific interest during the last decade, as a potential treatment target in primary and/or secondary prevention of CVD. Whereas there is a significant amount of evidence, stemming mainly from observational studies, concerning the cardiovascular safety of IL-1 and IL-6 antagonists in patients with rheumatic diseases, evidence from relevant randomized controlled trials (RCTs) is rather scarce and conflicting, especially for patients without underlying rheumatic disease. In this review, we summarize and critically present the currently available evidence, both from RCTs and observational studies, concerning the place that IL-1 and IL-6 antagonists may hold in the treatment of CVD.

show abstract

Section: Future Perspectives and Concluding Remarksmentioning

confidence: 99%